IMMP
Price
$1.61
Change
-$0.06 (-3.59%)
Updated
Apr 3 closing price
Capitalization
238.01M
54 days until earnings call
PRRUF
Price
$0.20
Change
-$0.00 (-0.00%)
Updated
Feb 18 closing price
Capitalization
238.01M
Ad is loading...

IMMP vs PRRUF

Header iconIMMP vs PRRUF Comparison
Open Charts IMMP vs PRRUFBanner chart's image
Immutep
Price$1.61
Change-$0.06 (-3.59%)
Volume$174.48K
Capitalization238.01M
Immutep
Price$0.20
Change-$0.00 (-0.00%)
Volume$5K
Capitalization238.01M
IMMP vs PRRUF Comparison Chart
Loading...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMMP vs. PRRUF commentary
Apr 04, 2025

To understand the difference between Immutep Limited - ADR (IMMP) vs. Immutep Limited (PRRUF) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (IMMP: $1.61 vs. PRRUF: $0.20)
Brand notoriety: IMMP and PRRUF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMMP: 233% vs. PRRUF: 131%
Market capitalization -- IMMP: $238.01M vs. PRRUF: $238.01M
IMMP [@Biotechnology] is valued at $238.01M. PRRUF’s [@Biotechnology] market capitalization is $238.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMMP’s FA Score shows that 0 FA rating(s) are green whilePRRUF’s FA Score has 0 green FA rating(s).

  • IMMP’s FA Score: 0 green, 5 red.
  • PRRUF’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMMP and PRRUF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMMP’s TA Score shows that 4 TA indicator(s) are bullish.

  • IMMP’s TA Score: 4 bullish, 4 bearish.

Price Growth

IMMP (@Biotechnology) experienced а -11.54% price change this week, while PRRUF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

IMMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMMP($238M) and PRRUF($238M) have the same market capitalization . PRRUF YTD gains are higher at: -1.937 vs. IMMP (-25.806). IMMP (-43.83M) and PRRUF (-43.83M) have comparable annual earnings (EBITDA) . IMMP (159M) and PRRUF (159M) have equal amount of cash in the bank . IMMP (1.69M) and PRRUF (1.69M) have identical debt. IMMP (0) and PRRUF (0) have equivalent revenues.
IMMPPRRUFIMMP / PRRUF
Capitalization238M238M100%
EBITDA-43.83M-43.83M100%
Gain YTD-25.806-1.9371,332%
P/E RatioN/AN/A-
Revenue00-
Total Cash159M159M100%
Total Debt1.69M1.69M100%
FUNDAMENTALS RATINGS
IMMP vs PRRUF: Fundamental Ratings
IMMP
PRRUF
OUTLOOK RATING
1..100
5442
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
7972
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMMP's Valuation (84) in the Biotechnology industry is in the same range as PRRUF (85) in the null industry. This means that IMMP’s stock grew similarly to PRRUF’s over the last 12 months.

IMMP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRRUF (100) in the null industry. This means that IMMP’s stock grew similarly to PRRUF’s over the last 12 months.

IMMP's SMR Rating (96) in the Biotechnology industry is in the same range as PRRUF (96) in the null industry. This means that IMMP’s stock grew similarly to PRRUF’s over the last 12 months.

PRRUF's Price Growth Rating (72) in the null industry is in the same range as IMMP (79) in the Biotechnology industry. This means that PRRUF’s stock grew similarly to IMMP’s over the last 12 months.

PRRUF's P/E Growth Rating (100) in the null industry is in the same range as IMMP (100) in the Biotechnology industry. This means that PRRUF’s stock grew similarly to IMMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMMP
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LANC175.091.55
+0.89%
Lancaster Colony Corp
NWN43.360.20
+0.46%
Northwest Natural Holding Company
PSTL14.09-0.13
-0.91%
Postal Realty Trust
EPD33.47-0.58
-1.70%
Enterprise Products Partners LP
LITB2.23-0.05
-2.19%
LightInTheBox Holding Co Ltd

PRRUF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRRUF has been loosely correlated with IMMP. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PRRUF jumps, then IMMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRRUF
1D Price
Change %
PRRUF100%
N/A
IMMP - PRRUF
43%
Loosely correlated
-3.59%
CALC - PRRUF
24%
Poorly correlated
-2.16%
PHGUF - PRRUF
21%
Poorly correlated
N/A
PVCT - PRRUF
11%
Poorly correlated
N/A
OXBDF - PRRUF
9%
Poorly correlated
N/A
More